We are forever grateful to Tom for his decades of leadership and passionate commitment to driving innovation in areas of urgent therapeutic need in the biopharmaceutical field. Tom reached the lives of many through his visionary thinking and entrepreneurial spirit. He was intimately involved in the advancement of the roxadustat and pamrevlumab programs, and the underlying technologies supporting these.
Tom’s contribution as a pioneer in the biotechnology industry will be measured by the lives he has and will continue to touch through FibroGen’s development of medicines for unmet medical needs. The FibroGen Board and management team are committed to fulfill and build on Tom’s vision.